pCPA Activity Overview
Status | Total Negotiations | Summary |
---|---|---|
Active Negotiations | 35 | Non-oncology: 22 Oncology: 13 |
Under Consideration for Negotiation | 11 | Non-oncology: 6 Oncology: 5 |
Completed Negotiations | 812 | With Letter of Intent: 703 Without agreement: 109 |
Negotiations That Were Not Pursued | 109 |
pCPA activity in the last four weeks
Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.
Engagement letters issued in the last four weeks
Brand Name | Manufacturer | Indication | Engagement Date |
---|---|---|---|
Rystiggo | UCB Canada Inc. | Generalized myasthenia gravis (gMG) | |
Pemazyre | Incyte Biosciences Canada Corporation | For the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement. | |
Imfinzi | AstraZeneca Canada Inc. | in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment | |
Vemlidy | Gilead Sciences Canada Inc. | chronic Hepatitis B virus | |
Spevigo | Boehringer Ingelheim (Canada) Ltd. | generalized pustular psoriasis (GPP) | |
Imdelltra | Amgen Canada Inc. | For the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after at least two prior lines of therapy including platinum-based chemotherapy | |
Fabhalta | Novartis Pharmaceuticals Canada Inc. | Paroxysmal nocturnal hemoglobinuria (PNH) |